Secukinumab, a human monoclonal antibody targeting interleukin-17A (IL-17A), is widely used for treating immunoinflammatory disorders. While effective, drug-induced uveitis (DIU) is a rare but serious adverse effect associated with biologic medications like TNF-α inhibitors and more recently, IL-17 inhibitors such as secukinumab. We present a case of posterior uveitis in a 42-year-old male with AS who developed ocular symptoms two years after starting secukinumab. The patient experienced a rapid decline in vision, eventually leading to blindness in one eye despite corticosteroid treatment. A literature review identified seven cases of secukinumab-associated uveitis, most of which were anterior and bilateral. In these cases, patients responded to corticosteroids, and many continued secukinumab without recurrence. However, in our case, posterior uveitis developed, and the patient’s condition worsened despite standard therapy. Secukinumab-induced uveitis though rare, can be severe and may require immediate ophtalmologic intervention. Clinicians should be aware of this paradoxial effect, particularly as biologic therapies are increasingly used. Further research is essential to better understand the mechanisms and risk factors associated with this adverse event.

Ankylosing spondylitis, Chorioretinitis, Uveitis, Secukinumab, IL17A inhibitors, Drug adverse reaction